TW201734041A - 抗il-17c抗體 - Google Patents

抗il-17c抗體 Download PDF

Info

Publication number
TW201734041A
TW201734041A TW106105384A TW106105384A TW201734041A TW 201734041 A TW201734041 A TW 201734041A TW 106105384 A TW106105384 A TW 106105384A TW 106105384 A TW106105384 A TW 106105384A TW 201734041 A TW201734041 A TW 201734041A
Authority
TW
Taiwan
Prior art keywords
seq
antibody
region
antibody fragment
amino acid
Prior art date
Application number
TW106105384A
Other languages
English (en)
Chinese (zh)
Inventor
珍 多米尼克 哈斯
茱爾珍 克拉提克
尼克 厄尼斯 瑞尼 凡德吉思特
Original Assignee
莫菲西斯公司
葛萊伯格有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 莫菲西斯公司, 葛萊伯格有限公司 filed Critical 莫菲西斯公司
Publication of TW201734041A publication Critical patent/TW201734041A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW106105384A 2016-02-19 2017-02-17 抗il-17c抗體 TW201734041A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16156582 2016-02-19
EP16156651 2016-02-22

Publications (1)

Publication Number Publication Date
TW201734041A true TW201734041A (zh) 2017-10-01

Family

ID=58057136

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106105384A TW201734041A (zh) 2016-02-19 2017-02-17 抗il-17c抗體

Country Status (33)

Country Link
US (5) US20190048071A1 (https=)
EP (1) EP3416983B1 (https=)
JP (2) JP6535139B2 (https=)
KR (1) KR102715157B1 (https=)
CN (1) CN108699143B (https=)
AU (1) AU2017219837B2 (https=)
BR (1) BR112018016798A2 (https=)
CA (1) CA3014842A1 (https=)
CL (1) CL2018002340A1 (https=)
CO (1) CO2018008724A2 (https=)
CU (1) CU20180087A7 (https=)
CY (1) CY1124296T1 (https=)
DK (1) DK3416983T3 (https=)
EA (1) EA037813B1 (https=)
EC (1) ECSP18070641A (https=)
ES (1) ES2877376T3 (https=)
HR (1) HRP20211059T1 (https=)
HU (1) HUE054755T2 (https=)
IL (1) IL260733B2 (https=)
LT (1) LT3416983T (https=)
MA (2) MA44227B1 (https=)
MD (1) MD3416983T2 (https=)
MX (1) MX2018009860A (https=)
PH (1) PH12018501739A1 (https=)
PL (1) PL3416983T3 (https=)
RS (1) RS62012B1 (https=)
SG (1) SG11201806161TA (https=)
SI (1) SI3416983T1 (https=)
SM (1) SMT202100361T1 (https=)
TN (1) TN2018000289A1 (https=)
TW (1) TW201734041A (https=)
WO (1) WO2017140831A1 (https=)
ZA (1) ZA201806249B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10604566B2 (en) * 2015-10-05 2020-03-31 Galapagos Nv Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis
HRP20211059T1 (hr) * 2016-02-19 2021-10-01 Morphosys Ag Antitijela za il-17c
TW201919698A (zh) * 2017-09-25 2019-06-01 德商莫菲西斯公司 異位性皮炎之治療
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
IL292940A (en) * 2019-11-22 2022-07-01 Morphosys Ag Collection of extractant during antibody chromatography
EP4061825A1 (en) * 2019-11-22 2022-09-28 MorphoSys AG Method to increase antibody yield during ion exchange chromatography

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
AU2005295421A1 (en) 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation
US20070129302A1 (en) * 2005-10-18 2007-06-07 Zeren Gao Il-17c antagonists and methods of using the same
EP2064237A2 (en) 2006-10-18 2009-06-03 ZymoGenetics, Inc. Il-17c antagonists and methods of using the same
US20120201821A1 (en) * 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
US8367586B2 (en) 2010-11-19 2013-02-05 Morphosys Ag Collection and methods for its use
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
ME03073B (me) * 2011-10-19 2019-01-20 Galapagos Nv Ant agonisti il17с za lečenje zapaljenskih poremećaja
JP2015521591A (ja) * 2012-06-12 2015-07-30 オレガ・バイオテック Il−17アイソフォームのアンタゴニストおよびその使用
EP3233915B1 (en) * 2014-12-15 2024-08-28 MorphoSys AG Antibodies for il-17c
HRP20211059T1 (hr) 2016-02-19 2021-10-01 Morphosys Ag Antitijela za il-17c

Also Published As

Publication number Publication date
KR20180109977A (ko) 2018-10-08
JP2019511910A (ja) 2019-05-09
RS62012B1 (sr) 2021-07-30
CN108699143B (zh) 2021-11-09
MX2018009860A (es) 2019-03-28
WO2017140831A1 (en) 2017-08-24
LT3416983T (lt) 2021-07-12
ECSP18070641A (es) 2018-10-31
CN108699143A (zh) 2018-10-23
CU20180087A7 (es) 2019-03-04
US20190202906A1 (en) 2019-07-04
MA44227B1 (fr) 2021-06-30
IL260733B2 (en) 2024-03-01
US10633439B2 (en) 2020-04-28
US10259869B2 (en) 2019-04-16
MA44227A (fr) 2018-12-26
SMT202100361T1 (it) 2021-07-12
EA201891594A1 (ru) 2019-01-31
EP3416983B1 (en) 2021-04-07
US20250074978A1 (en) 2025-03-06
EP3416983A1 (en) 2018-12-26
JP6535139B2 (ja) 2019-06-26
IL260733B1 (en) 2023-11-01
DK3416983T3 (en) 2021-06-21
MD3416983T2 (ro) 2021-08-31
CL2018002340A1 (es) 2018-11-23
CY1124296T1 (el) 2022-11-25
TN2018000289A1 (en) 2020-01-16
PL3416983T3 (pl) 2021-10-25
SG11201806161TA (en) 2018-08-30
KR102715157B1 (ko) 2024-10-10
JP2019162119A (ja) 2019-09-26
CO2018008724A2 (es) 2018-08-31
ES2877376T3 (es) 2021-11-16
AU2017219837B2 (en) 2023-08-17
US11987621B2 (en) 2024-05-21
BR112018016798A2 (en) 2018-12-26
IL260733A (https=) 2018-09-20
HUE054755T2 (hu) 2021-09-28
PH12018501739A1 (en) 2019-06-10
MA43088B1 (fr) 2020-10-28
ZA201806249B (en) 2020-02-26
MA43088A1 (fr) 2019-05-31
SI3416983T1 (sl) 2021-08-31
HRP20211059T1 (hr) 2021-10-01
JP6916834B2 (ja) 2021-08-11
EA037813B1 (ru) 2021-05-24
US20190048071A1 (en) 2019-02-14
CA3014842A1 (en) 2017-08-24
US20180340024A1 (en) 2018-11-29
US20200216529A1 (en) 2020-07-09
AU2017219837A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
US20250074978A1 (en) Antibodies for il-17c
CN112166124A (zh) 拮抗性cd73抗体
JP7257971B2 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
CN113201073A (zh) 双特异性EGFR/c-Met抗体
US20230406922A1 (en) Humanized cd19 antibody and use thereof
JP7840312B2 (ja) 多重特異性結合性作用剤およびその使用
EP4403573A1 (en) Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
TW202241944A (zh) 新穎的抗gremlin1抗體
KR20220143882A (ko) 항-il-4r 항체를 함유하는 약학적 조성물 및 이의 용도
JP2024533488A (ja) 抗ヒトcd3抗体及びその応用
JP2025506143A (ja) 多重特異性結合性作用剤およびその使用
CN115135671A (zh) 抗白介素-23 p19的抗体及其使用方法
KR20210138674A (ko) Tsg-6 항체 및 그 용도
KR20240049304A (ko) 융합 단백질을 함유하는 약학적 조성물
TW202144005A (zh) 一種抗ox40抗體醫藥組成物及其用途
CN114787188A (zh) 用抗pd-1抗体治疗癌症的方法
HK1259711A1 (en) Antibodies for il-17c
HK1259711B (en) Antibodies for il-17c
JP2026513302A (ja) 抗il-25抗体及びその使用方法